Should clozapine be offered as a second-line antipsychotic?

被引：0
|
作者：
Butler, Emma [1 ]
Stratford, Melanie [2 ]
Jauhar, Sameer [3 ]
机构：
[1] South London & Maudsley NHS Fdn Trust, London, England
[2] Clozapine Support Grp, SOUTHAMPTON, England
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London SE5 8AB, England
来源：
LANCET PSYCHIATRY | 2025年 / 12卷 / 02期
关键词：
D O I：
10.1016/S2215-0366(24)00440-1
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [21] Second-line option for metastatic RCC
    Vanessa Marchesi
    Nature Reviews Clinical Oncology, 2013, 10 (6) : 305 - 305
  • [22] The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors
    Krawczyk, Pawel
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Mlak, Radoslaw
    Jaskiewicz, Piotr
    Kucharczyk, Tomasz
    Winiarczyk, Kinga
    Krzakowski, Maciej
    Milanowski, Janusz
    CHEMOTHERAPY, 2012, 58 (01) : 60 - 69
  • [23] Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - YES
    Freedman, Mark
    Atkins, Harold L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1258 - 1259
  • [24] Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"
    Lohse, Ansgar W.
    Sebode, Marcial
    Vesterhus, Mette
    JOURNAL OF HEPATOLOGY, 2021, 74 (03) : 755 - 756
  • [25] Effective Alternative for Second-Line Therapy
    不详
    OBESITY FACTS, 2009, 2 (01) : 57 - 57
  • [26] Amfebutamone for second-line treatment only
    Reactions Weekly, 2001, 873 (1) : 2 - 2
  • [27] Second-line treatment for faecal incontinence
    Baeten, CGMI
    Uludag, Ö
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 : 72 - 75
  • [28] Axitinim believe in Second-Line Therapy
    Roos, Frederik
    AKTUELLE UROLOGIE, 2012, 43 (03) : 135 - 137
  • [29] Unravelling intertwined second-line options
    Diana Romero
    Nature Reviews Clinical Oncology, 2017, 14 : 197 - 197
  • [30] RAISE in second-line options for mCRC
    David Killock
    Nature Reviews Clinical Oncology, 2015, 12 : 373 - 373
12345